Suppr超能文献

人博卡病毒 1 型衣壳蛋白促进腺相关病毒基因组转导雪貂气道。

Human Bocavirus Type-1 Capsid Facilitates the Transduction of Ferret Airways by Adeno-Associated Virus Genomes.

机构信息

1 Department of Anatomy and Cell Biology, University of Iowa , Iowa City, Iowa.

2 Center for Gene Therapy, University of Iowa , Iowa City, Iowa.

出版信息

Hum Gene Ther. 2017 Aug;28(8):612-625. doi: 10.1089/hum.2017.060. Epub 2017 May 10.

Abstract

Human bocavirus type-1 (HBoV1) has a high tropism for the apical membrane of human airway epithelia. The packaging of a recombinant adeno-associated virus 2 (rAAV2) genome into HBoV1 capsid produces a chimeric vector (rAAV2/HBoV1) that also efficiently transduces human airway epithelia. As such, this vector is attractive for use in gene therapies to treat lung diseases such as cystic fibrosis. However, preclinical development of rAAV2/HBoV1 vectors has been hindered by the fact that humans are the only known host for HBoV1 infection. This study reports that rAAV2/HBoV1 vector is capable of efficiently transducing the lungs of both newborn (3- to 7-day-old) and juvenile (29-day-old) ferrets, predominantly in the distal airways. Analyses of in vivo, ex vivo, and in vitro models of the ferret proximal airway demonstrate that infection of this particular region is less effective than it is in humans. Studies of vector binding and endocytosis in polarized ferret proximal airway epithelial cultures revealed that a lack of effective vector endocytosis is the main cause of inefficient transduction in vitro. While transgene expression declined proportionally with growth of the ferrets following infection at 7 days of age, reinfection of ferrets with rAAV2/HBoV1 at 29 days gave rise to approximately 5-fold higher levels of transduction than observed in naive infected 29-day-old animals. The findings presented here lay the foundation for clinical development of HBoV1 capsid-based vectors for lung gene therapy in cystic fibrosis using ferret models.

摘要

人博卡病毒 1 型(HBoV1)对人呼吸道上皮的顶膜具有高亲嗜性。重组腺相关病毒 2(rAAV2)基因组包装到 HBoV1 衣壳中会产生嵌合载体(rAAV2/HBoV1),该载体也能有效地转导人呼吸道上皮细胞。因此,该载体在治疗囊性纤维化等肺部疾病的基因治疗中具有吸引力。然而,rAAV2/HBoV1 载体的临床前开发受到了限制,因为人类是 HBoV1 感染的唯一已知宿主。本研究报告 rAAV2/HBoV1 载体能够有效地转导新生(3-7 日龄)和幼龄(29 日龄)雪貂的肺部,主要是在远端气道。对雪貂近端气道的体内、体外和体外模型的分析表明,该特定区域的感染不如人类有效。对极化雪貂近端气道上皮细胞培养物中载体结合和内吞作用的研究表明,缺乏有效的载体内吞作用是体外转导效率低下的主要原因。虽然在感染后 7 天感染时,转基因表达随雪貂的生长呈比例下降,但在 29 天时用 rAAV2/HBoV1 再次感染雪貂会导致转导水平比未感染的 29 日龄动物高约 5 倍。本研究为使用雪貂模型在囊性纤维化的肺部基因治疗中基于 HBoV1 衣壳的载体的临床开发奠定了基础。

相似文献

引用本文的文献

2
Current landscape of cystic fibrosis gene therapy.囊性纤维化基因治疗的现状
Front Pharmacol. 2024 Oct 8;15:1476331. doi: 10.3389/fphar.2024.1476331. eCollection 2024.
6
Advances in the Cystic Fibrosis Drug Development Pipeline.囊性纤维化药物研发进展
Life (Basel). 2023 Aug 30;13(9):1835. doi: 10.3390/life13091835.
10
Gene therapy for cystic fibrosis: Challenges and prospects.囊性纤维化的基因治疗:挑战与前景。
Front Pharmacol. 2022 Oct 11;13:1015926. doi: 10.3389/fphar.2022.1015926. eCollection 2022.

本文引用的文献

2
Human Parvoviruses.人类细小病毒
Clin Microbiol Rev. 2017 Jan;30(1):43-113. doi: 10.1128/CMR.00040-16.
5
AAV-Mediated Gene Therapy for Research and Therapeutic Purposes.AAV 介导的基因治疗用于研究和治疗目的。
Annu Rev Virol. 2014 Nov;1(1):427-51. doi: 10.1146/annurev-virology-031413-085355.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验